Solid-dose tablet and capsule manufacturing is a mainstay of the pharmaceutical industry, as it results in a consistent, effective, and economical platform for drug delivery. Not only are tablets and capsules convenient and easy for consumers to handle, they are also very stable and have a high throughput, offering benefits to both consumers and pharmaceutical companies alike. Technological advances, combined with increasingly potent active pharmaceutical ingredients (APIs), have resulted in the availability of complex delivery systems such as controlled- and extended-release tablets and capsules that enhance therapeutic efficacy while minimizing adverse events.1 Although the number of novel APIs available for development has decreased, the complexity of solid-dose formulations has dramatically increased. Moreover, as complex, brand-name medications reach the end of their product lifecycle, generic equivalents will need to be produced that meet the same technology-enhanced high quality standards. This paradigm necessitates a greater flexibility on behalf of the manufacturer in order to meet the production requirements of a wide range of drug formulations while maintaining efficient and cost-effective manufacturing processes.